^
Association details:
| Biomarker: | FOLR1 expression |
|---|---|
| Cancer: | Solid Tumor |
| Drug: | farletuzumab ecteribulin (MORAb-202) (Microtubule inhibitor, Folate receptor 1-targeted antibody-drug conjugate) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
First-in-human Phase 1 Study of MORAb-202, An Antibody-drug Conjugate Comprising Farletuzumab Linked to Eribulin Mesylate, in Patients with Folate Receptor-a-positive Advanced Solid Tumors
Published date:
04/29/2021
Excerpt:
FRα-positive solid tumors who failed to respond to standard therapy were eligible. Patients received MORAb-202...Complete response, partial response, and stable disease were observed in one, nine, and eight patients, respectively....MORAb-202 demonstrated promising antitumor activity in FRα-positive solid tumors...
DOI:
10.1158/1078-0432.CCR-20-4740
Trial ID:
